Within the baricitinib group, patients experienced a mean Vitiligo Area Scoring Index score change of 44.8% from baseline to week 36. In contrast, the placebo group saw a 9.2% change. The Janus ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition of the skin, hair, nails, mouth and ...

Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study.

Baricitinib, a Janus kinase (JAK) inhibitor, combined with narrowband ultraviolet B (UVB) phototherapy, reduced disease activity and improved repigmentation and quality of life in adults with ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with extensive vitiligo see significantly more repigmentation compared with a ...

Subscribe for FREE The researchers then used baricitinib, a medication that selectively blocks the specific inflammatory pathways of lichen planus, to treat patients in the study. Cytokines are small ...

Baricitinib tablets are prescribed to treat adult patients suffering from moderate to severe rheumatoid arthritis who show loss of response to one or more tumor necrosis factor antagonist ...